Doris Makari

Articles by Doris Makari

105 Real-World Overall Survival With Palbociclib Plus an Aromatase Inhibitor (AI) in Overweight/Obese Patients With HR+/HER2− Metastatic Breast Cancer (MBC)

ByAdam M. Brufsky, MD, PhD,Neil M. Iyengar, MD,Xianchen Liu,Benjamin Li,Doris Makari,Lynn McRoy,Aaron B. Cohen,Melissa Estevez,Vandana G. Abramson,Rachel M. Layman,Giuseppe Curigliano

May 18th 2026

10 Real-World Effectiveness of Palbociclib (PAL) Plus Aromatase Inhibitors (AI) in Patients With Metastatic Breast Cancer (MBC) and Cardiovascular Diseases (CVD)

10 Real-World Effectiveness of Palbociclib (PAL) Plus Aromatase Inhibitors (AI) in Patients With Metastatic Breast Cancer (MBC) and Cardiovascular Diseases (CVD)

ByAdam M. Brufsky, MD, PhD,Xianchen Liu,Benjamin Li,Lynn McRoy,Connie Chen,Doris Makari,Rachel M. Layman,Hope S. Rugo, MD

August 20th 2024

27 CARDIAC-STAR: Prevalence of Cardiovascular (CV) Comorbidities in Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Metastatic Breast Cancer (mBC)

27 CARDIAC-STAR: Prevalence of Cardiovascular (CV) Comorbidities in Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Metastatic Breast Cancer (mBC)

ByHeather Moore,Avirup Guha,Doris Makari,Rachael McCaleb,Irene Arias,Stella Stergiopoulos,Benjamin Li,Michael Fradley,Susan Dent, MD

July 25th 2024

Latest Updated Articles

Trending on CancerNetwork

Acting on a HER2 Result and Navigating Access to Therapy

Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications

The Case for Frontline Zongertinib in HER2-Mutant NSCLC

Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC

Patient-Centered Treatment Transitions in HR+/HER2− mBC